Novo Nordisk's FY2024 results confirmed the structural nature of the GLP-1 demand wave: total revenues grew 26% to DKK 290.4 billion (approximately USD 41 billion), with Obesity care revenues up 56% to DKK 65.1 billion (approximately USD 8.2 billion)
They engage overlapping but not identical pathways, serve somewhat different experimental purposes, and have very different research depth in the published literature
Maleki D, Locke III GR, Camilleri M et al
If you have not been given that advice and your pharmacy hands you 8 mm, ask why
The right choice, however, depends on individual health needs, long-term goals, and a vision for how patients want to feel in their bodies
Emerging evidence also suggests potential cardiometabolic benefits, including improved lipid profiles and reduced inflammation